We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


SSB Presents the First Fully Integrated Upstream Platform

Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "SSB Presents the First Fully Integrated Upstream Platform"

First Name*
Last Name*
Email Address*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Sartorius Stedim Biotech (SSB) has developed an innovative and fully integrated technology platform to meet the requirements of upstream bioprocessing. It combines a top-performing expression system with outstanding equipment and process control for the rapid development and scale-up of robust, high-titer commercial manufacturing processes.

The biopharmaceutical industry is facing a series of challenges that it must address in order for it to deliver safe and efficacious products to a market made increasingly competitive by the emerge of biosimilar products. Companies must rapidly assess and then focus their investments on those drug candidates that have the greatest chance of being successful. To do this they must cut drastically early-stage development timelines and increase the speed with which they can reach the clinic.

The upstream technology platform, which combines a range of products and services that Sartorius Stedim Biotech has developed, addresses this challenge without compromising on product quality, process productivity or robustness. Biopharmaceutical manufacturers will be able to reach the clinic in 14 months by leveraging this new platform. The royalty-free CHO expression platform of SSB’s subsidiary Cellca delivers the titers required to meet companies’ cost of goods objectives. Cellca can establish a research cell bank for their clients within just 4 months.

The automated ambr15 micro bioreactor system is capable of controlling 24 or 48 micro bioreactor experiments. The system accelerates clone selection and scales up readily to BIOSTAT® STR single-use bioreactors, which biomanufacturers have successfully implemented at pilot and GMP production scales. To reduce early stage development timelines still further, Sartorius Stedim Biotech has integrated more than one hundred off-the-shelf and pre-qualified assays from BioOutsource into its platform allowing the rapid testing and analysis of biosimilar products.

“Our upstream platform is currently unique on the market and addresses customers’ needs and challenges of the biopharma industry in an exceptional way. It connects outstanding process technologies and brings biology to single-use bioprocessing. We are therefore introducing a whole new level of efficiency in upstream processing,” stated Stefan Schlack, Senior Vice President Marketing and Product Management Bioprocess Solutions at Sartorius Stedim Biotech.